Antibe Therapeutics (ATBPF) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free ATBPF Stock Alerts $0.22 0.00 (0.00%) (As of 05/24/2024) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 24, 2024 | finance.yahoo.comAntibe Announces Appointment of ReceiverApril 24, 2024 | businesswire.comAntibe Announces Appointment of ReceiverApril 19, 2024 | businesswire.comAntibe Provides Update on CCAA ProceedingsApril 16, 2024 | finance.yahoo.comAntibe Announces TSX Delisting ReviewApril 9, 2024 | businesswire.comAntibe Announces Granting of Initial Order Under Companies' Creditors Arrangement ActApril 9, 2024 | businesswire.comAntibe to File an Application for an Initial Order Under Companies' Creditors Arrangement ActApril 1, 2024 | finance.yahoo.comAntibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by NuanceMarch 20, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine MeetingMarch 7, 2024 | businesswire.comAntibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine MeetingMarch 4, 2024 | marketwatch.comAntibe Therapeutics Shares Sink After Arbitration Case LostFebruary 27, 2024 | benzinga.comAntibe Therapeutics Stock (OTC:ATBPF), Insider Trading ActivityFebruary 14, 2024 | finance.yahoo.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | businesswire.comAntibe Reports Q3 2024 Interim Financial and Operating ResultsNovember 13, 2023 | msn.comAntibe Therapeutics reports Q2 resultsNovember 9, 2023 | finance.yahoo.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationOctober 20, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 18, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationSeptember 8, 2023 | finance.yahoo.comAntibe Announces Results of 2023 Annual MeetingAugust 14, 2023 | finance.yahoo.comAntibe Reports Q1 2024 Interim Financial and Operating ResultsJune 29, 2023 | finance.yahoo.comAntibe Reports 2023 Year-End Results and Business HighlightsApril 12, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)April 6, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)March 12, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATBPF)February 16, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 15, 2023 | markets.businessinsider.comEchelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)February 9, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)February 7, 2023 | theglobeandmail.comAntibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)November 22, 2022 | finance.yahoo.comATBPF: On Track to Initiate Phase 2 Trial for Otenaproxesul in 1H23…October 12, 2022 | finance.yahoo.comAntibe Provides Development Update for OtenaproxesulSeptember 9, 2022 | finance.yahoo.comAntibe Announces Results of 2022 Annual MeetingSeptember 6, 2022 | finance.yahoo.comAntibe Academic Collaborator to Present Clinical Data at PAINWeek 2022July 8, 2022 | finance.yahoo.comATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…July 2, 2022 | finance.yahoo.comWill Antibe Therapeutics (TSE:ATE) Spend Its Cash Wisely?June 30, 2022 | finance.yahoo.comAntibe Therapeutics Reports 2022 Year-End Results and Business HighlightsApril 25, 2022 | nz.finance.yahoo.comAntibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceFebruary 16, 2022 | seekingalpha.comAntibe Therapeutics GAAP EPS of -$0.09February 14, 2022 | finance.yahoo.comAntibe Therapeutics Reports Q3 2022 Interim Financial and Operating ResultsJanuary 28, 2022 | nasdaq.comATBPF Real-Time QuotesDecember 1, 2021 | finance.yahoo.comATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…October 14, 2021 | msn.comBRIEF-Antibe Therapeutics Provides Update On Otenaproxesul And Expanded Drug PipelineOctober 14, 2021 | finance.yahoo.comAntibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug PipelineAugust 19, 2021 | finance.yahoo.comAntibe Therapeutics Announces Results of 2021 Annual MeetingAugust 17, 2021 | businesswire.comAntibe Therapeutics Reports Q1 2022 Interim Financial and Operating ResultsAugust 4, 2021 | finance.yahoo.comATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial… Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter. Email Address The only trade perfect for TSLA (Ad)Tesla is one of the most envied companies in the world… The stock has averaged a 37% annual return over the last decade. In fact, it’s up 2,136% in that time. Yet many folks think they’re “too late” to tap into the power of TSLA… But one trading expert from Florida says there’s still a massive opportunity buried inside its shares… According to his research, this opportunity would’ve allowed everyday traders to target gains of 100% or more… in sx days or less It’s all thanks to something called The Perfect Tesla Trade. >> Click here to join Lance now and he’ll teach you how to execute the Perfect Tesla Trade inside yo ATBPF Media Mentions By Week ATBPF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATBPF News Sentiment▼0.000.92▲Average Medical News Sentiment ATBPF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATBPF Articles This Week▼00▲ATBPF Articles Average Week Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MBRX News Today AVTX News Today ABVC News Today ERNA News Today GHSI News Today MNPR News Today VAXX News Today GRTX News Today LTUS News Today ELAB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ATBPF) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesWARNING about the death of the U.S. dollar…Colonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDigitizing the $11T commodities sector with one tiny stockResource Stock DigestThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
